Skip to main content
Clinical Trials/NCT04357197
NCT04357197
Withdrawn
Not Applicable

Closed-loop Control of Vasopressor Infusion in Critically Ill Patients: A Case Series

Erasme University Hospital0 sitesSeptember 25, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Diseases
Sponsor
Erasme University Hospital
Primary Endpoint
Percentage of case Time in hypotension (MAP <72 mmHg)
Status
Withdrawn
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this case series is to evaluate the performance of a novel closed-loop (automated) vasopressor administration system that delivers norepinephrine using feedback from standard hemodynamic monitor (EV1000 Monitor) from Edwards Lifesciences (IRVINE, USA) in critically ill patients

Detailed Description

In this protocol, the investigators will report the percentage of case time in hypotension (defined as Mean arterial pressure (MAP) \< 72mmHg) during a two hours study protocol in critically ill patients. The target MAP will be set at 80 mmHg, and the definition of hypotension is a MAP \< 90% of MAP target ( 80 mmHg - 10% = 72 mmHg) The investigators want to demonstrate that the closed-loop system can prevent hypotension at this specific set point. The investigators will test the system in a short series of 10-12 critically ill patients in the ICU setting during a two hours study protocol. Participants will receive standard patient care Fluids will be given as a baseline crystalloid administration set at 1-2 ml/kg/h

Registry
clinicaltrials.gov
Start Date
September 25, 2020
End Date
January 1, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Erasme University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Alexandre Joosten, MD PhD

Principal Investigator

Erasme University Hospital

Eligibility Criteria

Inclusion Criteria

  • All patients in the intensive care unit (awake or under sedation)
  • Requiring norepinephrine to maintain a MAP of 80 mmHg
  • Equiped with an arterial line

Exclusion Criteria

  • Subjects under 18 years of age
  • Subject with Atrial Fibrillation
  • Subjects who are pregnant

Outcomes

Primary Outcomes

Percentage of case Time in hypotension (MAP <72 mmHg)

Time Frame: During thetwo hours study protocol

The primary outcome will be the percentage of case time in predefined MAP target

Secondary Outcomes

  • percentage of case time with MAP >88 mmHg with norepinephrine still running(During the two hours study protocol)
  • Amount of vasopressors received(During the two hours study protocol)

Similar Trials